INT180591

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.56
First Reported 2004
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 18
Total Number 18
Disease Relevance 8.46
Pain Relevance 3.44

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (CYP27A1) small molecule metabolic process (CYP27A1)
Anatomy Link Frequency
cartilage 14
joint 1
knee 1
CYP27A1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Osteoarthritis 665 99.40 Very High Very High Very High
rheumatoid arthritis 212 98.80 Very High Very High Very High
spinal inflammation 60 98.56 Very High Very High Very High
metalloproteinase 21 80.36 Quite High
Pain 41 75.00 Quite High
Inflammation 48 60.20 Quite High
corticosteroid 18 55.92 Quite High
backache 6 54.84 Quite High
methotrexate 12 46.76 Quite Low
cytokine 18 45.68 Quite Low
Disease Link Frequency Relevance Heat
Osteoarthritis 664 99.40 Very High Very High Very High
Hypercalcemia 115 98.92 Very High Very High Very High
Rheumatoid Arthritis 212 98.80 Very High Very High Very High
Low Back Pain 67 98.56 Very High Very High Very High
Disease 128 98.00 Very High Very High Very High
Obesity 89 96.56 Very High Very High Very High
Disease Progression 31 89.36 High High
Osteoporosis 92 88.60 High High
Ankylosis 3 76.48 Quite High
Pain 25 75.00 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Our data demonstrate that urinary CTX-II levels, which specifically indicate degradation of cartilage, are also increased and related to radiographic damage of the spine in patients with AS.
Protein_catabolism (degradation) of CTX-II in cartilage associated with spinal inflammation
1) Confidence 0.56 Published 2008 Journal Yonsei Medical Journal Section Body Doc Link PMC2615310 Disease Relevance 1.07 Pain Relevance 0.62
Levels of both CTX-II and CTX-I, as markers of cartilage and bone degradation respectively, decreased by approximately 50% in the treatment group compared with baseline, and CTX-II levels were restored to premenopausal levels.
Protein_catabolism (degradation) of CTX-II in cartilage
2) Confidence 0.50 Published 2010 Journal BMC Musculoskelet Disord Section Body Doc Link PMC2902412 Disease Relevance 0.45 Pain Relevance 0.16
Levels of both CTX-II and CTX-I, as markers of cartilage and bone degradation respectively, decreased by approximately 50% in the treatment group compared with baseline, and CTX-II levels were restored to premenopausal levels.
Protein_catabolism (degradation) of CTX-I in cartilage
3) Confidence 0.50 Published 2010 Journal BMC Musculoskelet Disord Section Body Doc Link PMC2902412 Disease Relevance 0.45 Pain Relevance 0.16
The urinary marker of cartilage degradation, CTX-II, had decreased significantly at 2 years within the HRT group (P = 0.023) in comparison with baseline values.


Protein_catabolism (degradation) of CTX-II in cartilage
4) Confidence 0.49 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC546286 Disease Relevance 0 Pain Relevance 0
Increasing KL score was not correlated with bone resorption, but was significantly associated with the cartilage degradation CTX-II marker in both men and women (p = 0.007).
Protein_catabolism (degradation) of CTX-II in cartilage associated with hypercalcemia
5) Confidence 0.43 Published 2010 Journal BMC Musculoskelet Disord Section Abstract Doc Link PMC2902412 Disease Relevance 1.00 Pain Relevance 0.21
In conclusion, the review of the literature suggests that higher doses of risedronate (15 mg/day) strongly reduces the marker of cartilage degradation (CTX-II), which could contribute to attenuation of radiological progression of OA by preserving the structural integrity of subchondral bone.
Protein_catabolism (degradation) of CTX-II in cartilage associated with osteoarthritis
6) Confidence 0.40 Published 2010 Journal Yonsei Medical Journal Section Body Doc Link PMC2824859 Disease Relevance 0.86 Pain Relevance 0.35
CTX-II is a marker of cartilage degradation, while radiological progression of knee OA might be associated with subchondral bone structure.
Protein_catabolism (degradation) of CTX-II in knee associated with osteoarthritis
7) Confidence 0.40 Published 2010 Journal Yonsei Medical Journal Section Body Doc Link PMC2824859 Disease Relevance 0.59 Pain Relevance 0.26
The effect of risedronate on bone turnover helps to preserve the trabcular architecture and thus improve bone strength in humans.23 The results of the present review of the literature show that higher doses of risedronate (15 mg/day) strongly reduce the marker of cartilage degradation (CTX-II), which could contribute to attenuation of radiological progression of OA by preserving the structural integrity of subchondral bone.
Protein_catabolism (degradation) of CTX-II in cartilage associated with osteoarthritis
8) Confidence 0.40 Published 2010 Journal Yonsei Medical Journal Section Body Doc Link PMC2824859 Disease Relevance 0.90 Pain Relevance 0.38
The results of these RCTs show that higher dose of risedronate (15 mg/day) strongly reduces the marker of cartilage degradation (CTX-II), which could contribute to attenuation of radiological progression of OA by preserving the structural integrity of subchondral bone.
Protein_catabolism (degradation) of CTX-II in cartilage associated with osteoarthritis
9) Confidence 0.40 Published 2010 Journal Yonsei Medical Journal Section Body Doc Link PMC2824859 Disease Relevance 0.65 Pain Relevance 0.32
The type I collagen degradation marker ICTP (C-terminal telopeptide of type I collagen) and the cartilage markers CTX-II (C-terminal telopeptide fragments of type II collagen) and cartilage oligomeric matrix protein (COMP) were associated with the Larsen score at baseline.
Protein_catabolism (degradation) of CTX-II in cartilage
10) Confidence 0.38 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC546286 Disease Relevance 0.59 Pain Relevance 0.18
HRT caused a pronounced decrease in the collagen type I degradation marker, CTX-I, both when the HRT and control groups were compared (P < 0.001) and within the HRT group (P < 0.001) (Fig. 1a).
Protein_catabolism (degradation) of CTX-I
11) Confidence 0.32 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC546286 Disease Relevance 0 Pain Relevance 0.03
The CTX-I marker has been less used in RA, but some recent studies have reported that high levels of CTX-I and CTX-II, reflecting bone and cartilage degradation, respectively, were associated with an increased risk of radiological progression in RA [18,20,36].
Protein_catabolism (degradation) of CTX-I in cartilage associated with rheumatoid arthritis
12) Confidence 0.32 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC546286 Disease Relevance 0.39 Pain Relevance 0.14
The CTX-I marker has been less used in RA, but some recent studies have reported that high levels of CTX-I and CTX-II, reflecting bone and cartilage degradation, respectively, were associated with an increased risk of radiological progression in RA [18,20,36].
Protein_catabolism (degradation) of CTX-II in cartilage associated with rheumatoid arthritis
13) Confidence 0.32 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC546286 Disease Relevance 0.38 Pain Relevance 0.14
Bone turnover was studied by analyzing serum levels of C-terminal telopeptide fragments of type I collagen (CTX-I), C-terminal telopeptide of type I collagen (ICTP), bone sialoprotein, and C-terminal propeptide of type I procollagen (PICP) and cartilage turnover by urinary levels of collagen type II C-telopeptide degradation fragments (CTX-II) and cartilage oligomeric matrix protein (COMP) in serum.
Protein_catabolism (degradation) of CTX-II in cartilage
14) Confidence 0.28 Published 2004 Journal Arthritis Res Ther Section Abstract Doc Link PMC546286 Disease Relevance 0.23 Pain Relevance 0.08
The results of these RCTs show that risedronate reduces the marker of cartilage degradation (CTX-II), which could contribute to attenuation of radiological progression of OA by preserving the structural integrity of subchondral bone.
Protein_catabolism (degradation) of CTX-II in cartilage associated with osteoarthritis
15) Confidence 0.26 Published 2010 Journal Yonsei Medical Journal Section Abstract Doc Link PMC2824859 Disease Relevance 0.42 Pain Relevance 0.21
The review of the literature suggests that higher doses of risedronate (15 mg/day) strongly reduces the marker of cartilage degradation (CTX-II), which could contribute to attenuation of radiological progression of OA by preserving the structural integrity of subchondral bone.



Protein_catabolism (degradation) of CTX-II in cartilage associated with osteoarthritis
16) Confidence 0.26 Published 2010 Journal Yonsei Medical Journal Section Abstract Doc Link PMC2824859 Disease Relevance 0.32 Pain Relevance 0.16
The concentration of CTX-II, a degradation product from collagen II, was not affected by a single bout of exercise in our subjects, and it is likely that the systemic measurement was too crude and insensitive to be able to detect any contribution from a single joint.
Protein_catabolism (degradation) of CTX-II in joint
17) Confidence 0.10 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2945016 Disease Relevance 0.07 Pain Relevance 0.03
The bone formation marker bone alkaline phosphatase (b-ALP), and the bone resorption marker C-telopeptides crosslinks of type-1 collagen (S-CTX) were centrally assessed (Supreme, Liège, Belgium). b-ALP was assayed by immunoradiometric assay (Tandem®-ROstase®, Beckman Coulter, San Diego, CA, USA), and S-CTX was assayed using an enzyme-linked immunosorbent assay (Serum CrossLaps®ELISA, Nordic Bioscience Diagnostic, Herlev, Denmark).
Protein_catabolism (assayed) of S-CTX associated with hypercalcemia
18) Confidence 0.04 Published 2010 Journal Rheumatol Int Section Body Doc Link PMC2908746 Disease Relevance 0.10 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox